[1] Cheuk-Fung Yip T, Wai-Sun Wong V, Lik-Yuen Chan H, et al. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China. Gastroenterology, 2019.
[2] Choi J, Kim HJ, Lee J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B. JAMA Oncol, 2019,5:30.
[3] Kim SU, Seo YS, Lee HA, et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. J Hepatol,2019,71:456-464.
[4] Gordon SC, Zhou Y, Li J, et al. LBP-13-Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U.S. Cohort. J Hepatol, 2019,70:e147.
[5] Koike K, Suyama K, Ito H, et al. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naïve chronic hepatitis B patients. Hepatol Res, 2018,48:59-68. |
